Jinsy Andrews, an associate professor in the Department of Neurology at the Vagelos College of Physicians and Surgeons, speaks about the big difference between Aduhelm and AMX0035.
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
An experimental drug first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS is now being tested in ALS patients
Six Columbia University scientists have received NIH High-Risk, High-Reward grants that are given to exceptionally creative scientists proposing unconventional, but potentially high-impact, research
Neil Shneider, Stockman-Mauriello’s doctor and director of the Eleanor and Lou Gehrig ALS Center at Columbia University in New York, nonetheless asked Biogen for access.